Regulatory aspects for Biologic product licensing in India
Journal Title: International Journal of Drug Regulatory Affairs - Year 2019, Vol 7, Issue 1
Abstract
Biologics are the medicinal/ therapeutic/ diagnostic/ preventive preparations composed or derived from living organisms and their spin-off for human use. They include serums, vaccines, antitoxins, blood, antigens and blood components, gene therapy, tissues etc. Biotechnology is used as a unique approach in manufacturing such medicinal agents. The Indian National regulatory authority (CDSCO) is the body that is responsible for manufacturing and import of biological products in India. Biotechnology provides innovative solutions to medical field with more than 200 biologic medicines and vaccines. These developments benefits millions of patients worldwide and more than 600 products under development. At present these products can also be produced by manufacturers other than the innovator, with the expiry of some of patents. These new biotechnological medicines commonly referred to as „similar biologics‟ offer a major opportunity to provide greater access to reasonable healthcare for several lifesaving medicines. India has emerged as one of the leading providers to the world market for „Biosimilars‟. These may be considered to be very essential economical and therapeutical element for the pharmaceutical market in India. The Indian National Regulatory Authority is considered to be responsible for evaluating safety, efficacy and quality of all pharmaceuticals in India. The Department of Biotechnology in India is the department that governs the development, pre-clinical studies of all Biologicals.
Authors and Affiliations
Sanjeev Kumar Maurya, Vikesh Shukla, Prachi Kaushik, SP Yamini Kanti, Anshul Bansal
Keywords
Related Articles
- EP ID EP495687
- DOI 10.22270/ijdra.v7i1.287
- Views 130
- Downloads 0
GERMANY PATENT SYSTEM – AN OVERVIEW
Patent is one of the intellectual property rights, by which the innovator gets exclusive rights or legal monopoly grated to an individual or a firm to make use or sell or reproduce and excluding others from doing so. The...
REGULATORY ROADMAP FOR NANOTECHNOLOGY BASED MEDICINES
Nanotechnology is emerging as one of the key technologies of the 21st century and is expected to enable developments across a wide range of sectors that can benefit citizens. Nanomedicine is an application of nanotechnol...
Drug approval process in India and Europe
Every time a new drug is developed it requires a great amount of research work in manufacturing, Pre- clinical Science, Controls, Chemistry & Clinical trials. Regulatory agencies have Drug Reviewers who has the responsib...
STEVIA AN UNTOUCHED NATURE’S GIFT CAN BE A BOON TO DIABETIC
Plants and fungi are a vital part of healthcare. Over 80% of the global population rely on traditional medicine, much of which is based on plant remedies. Traditional Chinese medicine alone uses over 5,000 plant species....
RISING AIR POLLUTION: DEMAND ACTION-DRIVEN ADVOCACY AND BEHAVIOUR CHANGE FOR HEALTHER LIVES
Air pollution is a major environmental health problem affecting the developing and the developed countries alike. The effects of air pollution on health are very complex as there are many different sources and their indi...